| | | 南京健友生化制药股份有限公司 关于子公司获得美国 FDA 依托泊苷注射液 药品生产场地转移注册批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （四）规 格：100 mg/5 mL, 500 mg/ 25 mL 和 1 g/50 mL （五）ANDA 号：074529 （六）申 请 人：Meitheal Pharmaceuticals, Inc. 二、药品其他相关情况 公司于近日收到美国 FDA 的通知，公司子公司 Meitheal 向美国 FDA 申报的 依托泊苷注射液，100 mg/5 mL, 500 mg/ 25 mL 和 1 g/50 mL（ANDA 号：074529） 生产场地转移至健进制药有限公司的申请已获得批准。 依托泊苷注射液参比制剂为 CORDEN PHARMA LATINA SPA 持有，于 1983 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公司 Meitheal Pharmaceuticals, Inc.（以下简称"Meitheal"）于近日收到美国食品 ...

Core Viewpoint - The company announced that its subsidiary, Meitheal Pharmaceuticals, Inc., received FDA approval for the production site transfer of Etoposide Injection in multiple dosages, which is expected to positively impact the company's operational performance [1] Group 1: FDA Approval - The FDA issued a production site transfer approval letter for Etoposide Injection (100mg/5mL, 500mg/25mL, and 1g/50mL) under ANDA number 074529 [1] - The approved production will take place at the subsidiary, Jianjin Pharmaceutical Co., Ltd. [1] Group 2: Financial Impact - The company has invested approximately 2.1561 million yuan in the research and development of Etoposide Injection [1] - The newly approved product is expected to be launched in the U.S. market soon, which may have a positive effect on the company's financial performance [1]

Core Viewpoint - Jingze Biopharma is preparing for an IPO, focusing on high-growth areas of assisted reproduction and ophthalmic drugs, with a pre-IPO valuation of 3.09 billion RMB after completing multiple funding rounds [1][2]. Company Overview - Jingze Biopharma specializes in assisted reproduction and ophthalmic drugs, having developed a comprehensive R&D system and commercial-scale production capabilities [2]. - The company has eight candidate drugs, with its first core product expected to generate revenue by 2026 [2][7]. Product Pipeline - The core product JZB30, a recombinant human follicle-stimulating hormone (rhFSH) lyophilized injection, is crucial in assisted reproduction and has received NDA approval [4][7]. - Another key product, JZB05, is an anti-VEGF intravitreal injection aimed at treating wet age-related macular degeneration (wAMD) and diabetic macular edema (DME), with expectations for commercialization by 2026 [5][6]. Market Potential - The assisted reproduction market is expanding due to relaxed fertility policies, with an estimated 59.2 million couples affected by infertility in China by 2024, projected to grow to 68.4 million by 2030 [8]. - The ophthalmic drug market is also growing, with a projected increase from 29.5 billion RMB in 2024 to 53.7 billion RMB by 2030, driven by rising rates of blindness-related eye diseases [12][13]. Financial Outlook - Jingze Biopharma is currently not profitable, with projected losses of 246 million RMB and 243 million RMB for 2023 and 2024, respectively [7]. - The company anticipates revenue generation starting in 2026 with the commercialization of JZB30, while R&D costs will continue to be a significant expense [7].

Group 1 - The 2024 list of China's top 100 pharmaceutical companies highlights the concentration and high-quality development of the pharmaceutical industry, with two companies from Nanjing, Xiansheng Pharmaceutical and Jianyou Co., Ltd., making the list [1] - Xiansheng Pharmaceutical has over 74% of its revenue coming from innovative drugs, with 10 innovative drugs launched, including the recently approved Enzeshushu, a targeted drug for platinum-resistant ovarian cancer [1] - Jianyou Co., Ltd. is a leading producer of heparin raw materials in China, successfully entering high-end markets in Europe and the United States, with a global customer base that includes Pfizer, Merck, and Sanofi [1] Group 2 - The "2025 China Drug R&D Strength Rankings" emphasizes "R&D value," with three companies from Nanjing's Jiangbei New District Biopharmaceutical Valley making the list, including Jianyou Co., Ltd. and Yaoshi Technology [2] - The rankings are based on various metrics, including drug approval status, R&D investment, clinical trial performance, and patent scores, reflecting the highest standards in China's CRO/CDMO industry [2] - Yaoshi Technology is recognized as a global leader in drug development, having collaborated with over 80% of the top 20 pharmaceutical companies worldwide [3] Group 3 - The Nanjing Jiangbei New District Biopharmaceutical Valley has gathered over 1,300 biopharmaceutical companies, indicating a robust industry cluster [4]

Core Viewpoint - Shanghai Xinyao Paike Medical Technology Co., Ltd. has successfully developed into a leading manufacturer of drug delivery devices, driven by a strong team spirit and a focus on addressing market pain points in the medical device sector [2][4][8]. Company Development - The company was founded by a team with extensive experience in the medical industry, who identified the market's reliance on foreign products and aimed to create high-end drug delivery devices for the Chinese market [4][5]. - Xinyao Paike has expanded its product offerings to include pre-filled syringes and self-injection pens, with a focus on chronic disease management [6][7]. Product Innovation - The company has achieved significant milestones in the development of needle protection devices, capturing over 90% of the domestic market share and establishing partnerships with leading pharmaceutical companies [5][8]. - Xinyao Paike's self-injection pens are designed for patients with chronic diseases, allowing for convenient at-home medication administration [7][8]. Market Strategy - The company emphasizes a market-driven approach to project selection, ensuring that all product developments are aligned with customer needs and market demands [6][8]. - Xinyao Paike has implemented a rigorous project approval process involving multiple departments to ensure the feasibility and foresight of new initiatives [8][9]. Team and Talent Development - The success of Xinyao Paike is attributed to a cohesive and collaborative founding team, which has fostered trust and efficiency in market execution [9]. - The company actively recruits talent through partnerships with educational institutions and industry networks, aiming to build a strong talent pipeline [9]. Future Outlook - Xinyao Paike plans to continue its focus on the drug delivery device sector, enhancing product quality and technology while expanding both domestic and international markets [9].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has announced a share buyback plan approved by its board and shareholders, with a total buyback amount between RMB 20 million and RMB 40 million, and a maximum price of RMB 18.75 per share [2] - The buyback is intended for employee stock ownership plans or equity incentives, with a buyback period of 12 months from the approval date [2] - As of June 30, 2025, the company has repurchased 880,000 shares, accounting for 0.05% of the total share capital, with a total expenditure of RMB 10.2207 million, excluding transaction fees and stamp duty [3] Group 2 - The company will adhere to relevant regulations and guidelines during the buyback period and will make decisions based on market conditions while fulfilling information disclosure obligations [5]

Group 1 - The company announced a share repurchase plan with a total expected amount between RMB 20 million and RMB 40 million [1][2] - The repurchase period is set from May 20, 2025, to May 19, 2026 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][2] Group 2 - As of June 30, 2025, the company has repurchased a total of 880,000 shares, accounting for 0.05% of the total share capital [2] - The total amount spent on the repurchase is RMB 10.2207 million, with a price range of RMB 11.58 to RMB 11.66 per share [2][3] - The company will continue to make repurchase decisions based on market conditions and will fulfill information disclosure obligations [3]

Core Viewpoint - Han Yu Pharmaceutical (300199.SZ) is experiencing a significant increase in net profit due to the approval and commercialization of its liraglutide injection in the U.S., marking a turnaround after seven years of losses in non-recurring net profit [2][4][8]. Financial Performance - The company expects a net profit attributable to shareholders of 142 million to 162 million yuan for the first half of the year, representing a year-on-year increase of 1470.82% to 1663.89% [2][4]. - The non-recurring net profit is projected to be between 122 million and 142 million yuan, showing a year-on-year growth of 304.27% to 337.76% [2][4]. - The company has turned around its non-recurring net profit after seven consecutive years of losses [8]. Product Development and Market Strategy - The approval of liraglutide injection by the FDA in December 2024 is a key driver of the company's revenue growth, with the product being the first generic version in the U.S. market [2][5]. - Han Yu has signed contracts worth 338 million yuan with Hikma to expand its market presence in the U.S. [2][5]. - The company has shipped nearly 1.8 million units of liraglutide to Hikma as part of its commercialization strategy [7]. Competitive Landscape - The company will face competition from other firms, including Jianyou Co., which also received FDA approval for its liraglutide injection [3][5]. - The global market for liraglutide is substantial, with a terminal market size of approximately 5.991 billion USD in 2023, and the U.S. market alone is about 3.204 billion USD [5][6]. - The competition includes both the original manufacturer Novo Nordisk and other generic entrants, which may impact market share [5][6]. Business Segments and Growth Potential - Han Yu's main business segments include peptide formulations, peptide raw materials, small nucleic acids, and CDMO/CMO services [8]. - The company has seen a significant increase in revenue from raw materials, which accounted for 44.04% of total revenue in 2024, up from 28.14% in 2023 [9]. - The company plans to enhance its raw material production capacity to 5-10 tons by 2025 and expand its global market penetration [9][10].

| | | 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 本次回购资金总额不低于人民币 2,000 万元（含）且不超过人民币 4,000 万 元（含），本次回购股份的价格不超过 18.75 元/股（含），本次回购的股份用于 员工持股计划或股权激励，回购股份实施期限为自公司股东大会审议通过本次回 购股份方案之日起 12 个月内。具体内容详见公司于 2025 年 4 月 29 日披露的《健 友股份关于以集中竞价交易方式回购股份的预案》（公告编号：2025-028）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，应于每个月的前 3 个交易日内 披露截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 6 月 30 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购股份 88 万股，已回购股份占公司总股本的比例为 0.05%，成交最 低价为 11.58 元/股，成交最高价为 11.66 元/股，支付的总金额为人民币 1,022.07 万元（不含交易费用及 ...

Core Viewpoint - The announcement details the conversion results of the "Jianyou Convertible Bonds" and the changes in the company's share capital as of June 30, 2025, highlighting the low conversion rate and the significant amount of unconverted bonds [1][2][3]. Summary by Sections Conversion Situation - As of June 30, 2025, a total of RMB 719,000 worth of "Jianyou Convertible Bonds" has been converted into common shares, resulting in 18,035 shares, which represents 0.001% of the total shares before conversion [2][6]. - The total amount of "Jianyou Convertible Bonds" that has not been converted is RMB 502,464,000, accounting for 99.86% of the total issuance [3][6]. Convertible Bond Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 503.19 million, with a maturity of 6 years, approved by the China Securities Regulatory Commission [4]. - The bonds were listed on the Shanghai Stock Exchange on May 22, 2020, under the code "113579" [4]. Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price to RMB 24.34 per share as of June 5, 2025 [5].